Outlook Therapeutics Inc. is a late clinical-stage biopharmaceutical company specializing in ophthalmology. The company is focused on developing and commercializing ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab designed for the treatment of retinal diseases, particularly neovascular or “wet” age-related macular degeneration (wet AMD). Its lead product candidate seeks to provide a standardized, rigorously tested alternative to repackaged intravenous bevacizumab commonly used off-label in retinal care today. By concentrating on retina specialists and eye-care providers, Outlook Therapeutics aims to address important needs in dosing consistency, sterility, and regulatory oversight for anti-VEGF therapies used in vision-threatening conditions. Headquartered in Iselin, New Jersey, and founded in the United States, the company operates within the broader biotechnology and pharmaceutical markets, with a clear emphasis on improving treatment options for patients with serious retinal disorders.